Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0316.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
With the Evrysdi Co-pay Program, eligible, commercially insured patients pay as little as $5 per 30-day supply of Evrysdi. The program covers the rest of the patient's co-pay or co-insurance, up to $25,000 in assistance per calendar year for drug costs.
There are no income requirements for the Evrysdi Co-pay Program.
*Commercial insurance includes plans you receive from your job or plans from the Health Insurance Marketplace. Government programs like Medicare and Medicaid are not commercial insurance.
If a patient is not eligible for the Evrysdi Co-pay Program, there may be other options for co-pay assistance. Call (833) 387-9734 or visit Genentech-Access.com/Evrysdi/patients to learn more.
Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Interactions with Substrates of MATE Transporters
Pregnancy & Breastfeeding
Potential Effects on Male Fertility
Most Common Adverse Reactions
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.